Glaxosmithkline | GSK - Interest Expense On Debt


Glaxosmithkline reported GBP192.73M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Amgen USD 95.64B 94.98B Jun/2026
AstraZeneca USD 340M 144M Jun/2026
Aurora Cannabis CAD 230K 1.88M Mar/2026
Bausch Health Companies USD 402M 5M Mar/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Canopy Growth CAD 12.31M 4.97M Mar/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Drreddys Laboratories INR 1.06B 113M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
GlaxoSmithKline GBP 121M 46M Jun/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
J&J USD 43M 25M Mar/2026
Merck USD 525M 46M Jun/2026
Novartis USD 462M 119M Jun/2026
Pacira USD 3.62M 77K Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Pfizer USD 667M 4M Jun/2026
Phibro Animal Health USD 11.91M 191K Dec/2025
Prestige Brands USD 13.94M 2.52M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 287M 109M Jun/2026
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Takeda JPY 63.85B 20.2B Jun/2026
Teva Pharmaceutical Industries USD 195M 21M Jun/2026
Zoetis USD 61M 1000K Jun/2026